Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13330960 | 1.00 | MEN1 (0.38) | MEN1MAPK1KMT2ATDP1HSD11B1 | |
| SCHEMBL22482737 | 1.00 | MEN1 (0.38) | MEN1MAPK1KMT2ATDP1HSD11B1 | |
| SCHEMBL3312164 | 1.00 | MEN1 (0.38) | MEN1MAPK1KMT2ATDP1HSD11B1 | |
| SCHEMBL15218631 | 0.88 | KMT2A (0.38) | MEN1MAPK1KMT2ATDP1CACNA1H | |
| SCHEMBL28747502 | 0.83 | KMT2A (0.35) | MEN1MAPK1KMT2ACACNA1HDPP8 | |
| SCHEMBL28687680 | 0.82 | MEN1 (0.34) | MEN1MAPK1KMT2AHSD11B1CACNA1H | |
| SCHEMBL28670731 | 0.82 | MEN1 (0.34) | MEN1MAPK1KMT2AHSD11B1CACNA1H | |
| SCHEMBL5428985 | 0.80 | MEN1 (0.42) | MEN1MAPK1KMT2ATDP1HSD11B1 | |
| SCHEMBL13742611 | 0.80 | MEN1 (0.42) | MEN1MAPK1KMT2ATDP1HSD11B1 | |
| SCHEMBL8089082 | 0.80 | MEN1 (0.42) | MEN1MAPK1KMT2ATDP1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115619-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| US-12227520-B2 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20230203061-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230027019-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2023-01-26 | — | — | US | disclosed |
| EP-4122537-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Gilead Sciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11548902-B1 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3938047-B1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2022-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115619-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZYX, CCNY, NCAPD3 | MEN1 3930/4885MAPK1 4209/4885KMT2A 2417/4885 |
| US-12227520-B2 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | ZYX, CCNY, XDH | MEN1 3841/4885MAPK1 4169/4885KMT2A 2126/4885 |
| US-11548902-B1 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | ZYX, CCNY, XDH | MEN1 3841/4885MAPK1 4169/4885KMT2A 2126/4885 |
| US-20230203061-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZYX, CCNY, XDH | MEN1 3841/4885MAPK1 4169/4885KMT2A 2126/4885 |
| US-20230027019-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZYX, CCNY, XDH | MEN1 3841/4885MAPK1 4169/4885KMT2A 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.